

Human Granzyme B



www.mesoscale.com®

Ordering Information

MSD Customer Service
Phone: 1-240-314-2795
Fax: 1-301-990-2776
Email: CustomerService@mesoscale.com

Scientific Support

Phone: 1-240-314-2798
Email: ScientificSupport@mesoscale.com


Company Address

Meso Scale Discovery
A division of
Meso Scale Diagnostics, LLC.
1601 Research Boulevard
Rockville, MD 20850-3173 USA

Product Options	Catalog Number	Description
Multiplex	K151AEM, K251AEM	U-PLEX Immuno-Oncology Group 1 (human)
	K151APDK-1/-2/-4	U-PLEX Human Granzyme B Assay with SECTOR™ plates
Singleplex	K151APDK-21/-22/-24	U-PLEX Human Granzyme B Assay with QuickPlex Ultra™ plates
	K251APDK-2/-4	U-PLEX Human Granzyme B Assay with 384-well plates
	B21APD-2/-3	U-PLEX Human Granzyme B Antibody Set
Protocol	U-PLEX Product Inserts are available at www.mesoscale.com	

The MESO SCALE DISCOVERY® U-PLEX platform was designed to provide ultimate flexibility for detection of biomarkers in a wide variety of sample types. This datasheet provides the representative performance of the U-PLEX® Human Granzyme B Assay tested on U-PLEX 96-well SECTOR plates run as a multiplex. The data do not represent the product specifications. Under your experimental conditions, the assay may perform differently from the representative data. U-PLEX assays are offered in either singleplex or multiplex; both are available on 96- or 384-well plates. See a U-PLEX product insert for instrument compatibility.

Representative Calibration Curve and Sensitivity



Assay	Median LLOD (pg/mL)	LLOD Range (pg/mL)
Granzyme B	0.09	0.06-0.15

The Calibrator curve was fitted with a 4-parameter logistic model with a 1/Y² weighting. The lower limit of detection (LLOD) is a calculated concentration corresponding to 2.5 standard deviations above the background (zero Calibrator).

Precision

Control	Average Conc. (pg/mL)	Average Intra-run Conc. (%CV)	Inter-run Conc. (%CV)
High	69	5.2	4.0
Mid	17	4.4	3.2
Low	4.3	5.1	2.3

Controls were made by spiking Calibrator into assay diluent at 3 levels within the quantitative range of the assay. Average intra-run concentration %CV is the average %CV of the control replicates within an individual run. Inter-run concentration %CV is the variability of controls across multiple runs.

For Research Use Only.
Not for use in diagnostic procedures.

MSD® U-PLEX Human Granzyme B

Tested Samples

Sample Type	Serum (N = 5)	EDTA Plasma (N = 5)	Normal Lysate (N = 5)	Tumor Lysate (N = 2)
Median (pg/mL)	1.5	3.2	163	2,100
Range (pg/mL)	1.1–2.0	2.2–7.5	51–767	250–3,960
% Detected	100	100	100	100

Normal serum and plasma samples were diluted 4-fold prior to the assay. Lysates were tested at a protein concentration of 0.5 mg/mL.

Dilution Linearity

Serum			EDTA Plasma		
Fold Dilution	Average % Recovery	% Recovery Range	Fold Dilution	Average % Recovery	% Recovery Range
2	79	76–82	2	81	79–83
8	106	102–113	8	103	99–105
16	104	84–119	16	101	83–108

Normal human serum and EDTA plasma were spiked with Calibrator and tested at different dilutions. Percent recovery at each dilution level was normalized to the dilution-adjusted, 4-fold concentration. Samples may benefit from additional dilution with assay diluent to reduce matrix effects.

$$\% \text{ Recovery} = (\text{measured concentration} / \text{expected concentration}) \times 100$$

Spike Recovery

Spike Level	Serum		EDTA Plasma	
	Average % Recovery	% Recovery Range	Average % Recovery	% Recovery Range
High	92	84–96	96	94–98
Mid	94	84–100	98	93–105
Low	98	85–106	101	97–104

Normal serum and plasma were spiked with Calibrator at 3 levels. Spiked samples were diluted 4-fold to determine the expected concentration of the analyte. Samples may benefit from additional dilution with assay diluent to reduce matrix effects.

$$\% \text{ Recovery} = (\text{measured concentration} / \text{expected concentration}) \times 100$$

Specificity

To assess specificity, the Granzyme B Antibody Set was tested individually against a larger panel of analytes for nonspecific binding: APRIL/TNFSF13, BAFF-R/TNFRSF13C, BCMA/TNFRSF17, CD20, CD27, CD276/B7-H3, CD28, CD40L (soluble), CTACK, CTLA-4, ENA-78, Eotaxin, Eotaxin-2, Eotaxin-3, EPO, E-Selectin, FGF (basic), FLT3L, Fractalkine, G-CSF, Galectin-9, GTR/TNFRSF18, GITRL/TNFSF18, GM-CSF, gp130 (soluble), Granzyme A, Granzyme B, GRO- α , HAVCR2/TIM-3, HVEM/TNFRSF14, I-309, ICOS, ICOSL/B7-H2, IFN- α 2a, IFN- β , IFN- γ , IL-1 α , IL-1 β , IL-1RA, IL-10, IL-12/IL-23p40, IL-12p70, IL-13, IL-15, IL-16, IL-17A, IL-17A/F, IL-17C, IL-17D, IL-17E/IL 25, IL-17F, IL-18, IL-2, IL-21, IL-22, IL-23, IL-27, IL-29/IFN- λ 1, IL-2R α , IL-3, IL-31, IL-33, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IP-10, I-TAC, LAG-3, LIGHT/TNFSF14, MCP-1, MCP-2, MCP-4, M-CSF, MDC, MIF, MIG, MIP-1 α , MIP-5, MMP-1, MMP-2, MMP-7, MMP-9, Nectin-4, OX40/TNFRSF4, PD1, PD-L1, PD-L2, Pentraxin 3, Perforin, PIGF, P-Selectin, RAGE (soluble), RANKL/TNFSF11, RANTES, S100A12, SDF-1 α , TARC, Tie-2, TIGIT, TLR-1, TNF-RI, TNF-RII, TNF- α , TNF- β , TPO, TRAIL, TSLP, VEGF-A, VEGF-D, VEGFR-1/Flt-1 and YKL-40. Nonspecific binding was less than 2.0%.

$$\% \text{ Nonspecificity} = (\text{nonspecific signal} / \text{specific signal}) \times 100$$

Diluent Compatibility

Diluents 58 and 3 are provided with this assay. MSD offers a range of assay and antibody diluents for separate purchase. Depending on your assay needs, other diluents may be tested.

Assay Components

Calibrator: Granzyme B is included in Calibrator 23. The human Granzyme B Calibrator is a full-length recombinant protein expressed in a mouse cell line.

Antibodies: The U-PLEX Human Granzyme B Assay uses a mouse monoclonal antibody for capture and a mouse monoclonal antibody for detection.

Assay generation: B

Note: This datasheet contains representative assay performance data. In custom multiplex formats, the assay may perform differently from the representative data shown.

